Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3913]

Part 3: How to test

PARP inhibition in the treatment of prostate cancer

Part 3: How to test ( PARP inhibition in the treatment of prostate cancer )

Prostate cancer screening using prostate-specific antigen, a multiplex blood...

Prof Martin Eklund - Karolinska Institutet, Solna, Sweden

Prostate cancer screening using prostate-specific antigen, a multiplex blood-test, MRI and targeted prostate biopsies ( Prof Martin Eklund - Karolinska Institutet, Solna, Sweden )

OncoAlert and ecancer weekly round up for July 12- July 18, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for July 12- July 18, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Mitomycin and BCG treatment vs BCG monotherapy in patients with non-muscle...

Dr Cosimo De Nunzio - Sant'Andrea Hospital, University La Sapienza, Rome, Italy

Mitomycin and BCG treatment vs BCG monotherapy in patients with non-muscle invasive bladder cancer ( Dr Cosimo De Nunzio - Sant'Andrea Hospital, University La Sapienza, Rome, Italy )

Cell free DNA BRAF mutant allele fraction and whole exome sequencing in...

Dr Elena Elez - Vall d'Hebron University Hospital, Barcelona, Spain

$Cell free DNA BRAF mutant allele fraction and whole exome sequencing in BRAFV600E metastatic colorectal cancer ( Dr Elena Elez - Vall d'Hebron University Hospital, Barcelona, Spain )$

New Director of the Cicely Saunders Institute at King’s College London

Prof Richard Harding - King's College London, London, UK

New Director of the Cicely Saunders Institute at King’s College London ( Prof Richard Harding - King's College London, London, UK )

FGFR as a tumour agnostic indicator and its importance in the diagnosis and...

Dr Christophe Massard and Prof Eva Compérat

FGFR as a tumour agnostic indicator and its importance in the diagnosis and treatment of multiple solid tumour types ( Dr Christophe Massard and Prof Eva Compérat )

ASCO 2021: Precision and molecular reporting for prostate cancer

Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA

ASCO 2021: Precision and molecular reporting for prostate cancer ( Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA )

Neo-AEGIS: Preliminary results of phase III RCT of CROSS versus perioperative...

Prof John Reynolds - Trinity College Dublin, Dublin, Republic of Ireland

Neo-AEGIS: Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy ( Prof John Reynolds - Trinity College Dublin, Dublin, Republic of Ireland )

COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory...

Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA

$COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer ( Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA )$

The clinical value of maintenance in multiple myeloma

Prof Wee Joo Chng - National University of Singapore, Singapore

The clinical value of maintenance in multiple myeloma ( Prof Wee Joo Chng - National University of Singapore, Singapore )

Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non...

Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA

$Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients ( Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA )$

More from ecancer